A practical reference on LC-MS: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-17 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
The Bushmaster project started as an offshoot of the US Army's MICV-65 program that was attempting to introduce a new infantry fighting vehicle to replace their existing M113 armored personnel carriers. Part of this program called for a new scout vehicle to replace the M114, a parallel development taking place under the XM800 Armored Reconnaissance Scout Vehicle. Both the XM800 and the cavalry version of the XM701 MICV vehicles were armed with the M139, a US-built version of the Hispano-Suiza HS.820 20 mm autocannon. During the testing phase, the Army eventually rejected the XM701 and started work on a newer design known as the XM723. Soon after the XM800 was also rejected. This led to the combination of the two programs, moving the scout role to the cavalry version of the XM723. At the same time, the M139 proved to be disappointing and a contract for a new weapon to replace it started as a competitive development in 1972 simultaneously at Ford's Aeronutronic Division with the PFB-25 (self-powered weapon) and the Hughes Helicopters' Ordnance Division (externally-powered,) under the Summa Corporation as the Vehicle Rapid-Fire Weapons System-Successor, or VRFWS-S. This was essentially a power-driven gun firing similar 20 mm ammunition to the HS.820, the power-driven mechanism was to ensure operation even in the case of a misfire. Progress on the VRFWS-S was slow, and eventually resulted in a switch to a much more powerful, 25 mm, round.
Desmoplastic melanocytic naevus Desmoplastic spitz naevus Desmoplastic cellular blue naevus Desmoplastic hairless hypopigmented naevus Desmoplastic trichoepithelioma Desmoplastic trichilemmoma Desmoplastic tumor of the follicular infundibulum Sclerotic dermatofibroma Desmoplastic fibroblastoma Desmoplastic cellular neurothekeoma Sclerosing perineurioma Microvenular haemangioma Immature scars
=== Dependence and withdrawal === Long-term use of high doses of tramadol causes physical dependence and withdrawal syndrome. These include both symptoms typical of opioid withdrawal and those associated with serotonin–norepinephrine reuptake inhibitor (SNRI) withdrawal; symptoms include numbness, tingling, paresthesia, and tinnitus. Psychiatric symptoms may include hallucinations, paranoia, extreme anxiety, panic attacks, and confusion. In most cases, tramadol withdrawal will set in 12–20 hours after the last dose, but this can vary. Tramadol withdrawal typically lasts longer than that of other opioids. Seven days or more of acute withdrawal symptoms can occur as opposed to typically 3 or 4 days for other codeine analogs.
Mamadou Amadou Ly - Educationist, first African to be awarded the Yidan Prize, Time Magazine 100 Most influential people in the world (2026), Senegal. Amsatou Sow Sidibé- academic, lawyer and politician, Senegal Adji Bousso Dieng - assistant Professor of artificial intelligence, First African Faculty school of Engineering and applied science, Princeton University, Senegal. Ayuba Suleiman Diallo - Fulani Muslim prince and merchant, from Bundu, who was captured and sold to European slave traders after having just sold slaves himself. Ba Mamadou Mbare – former president of the Senate of Mauritania and former acting president of Mauritania, in office 15 April 2009 – 5 August 2009. The first black leader of Mauritania Baaba Maal – Singer and guitarist – Senegal Babacar Ba - former minister of finance, Foreign minister of Senegal. Cheikh Tidiane Gadio - Diplomat, former Minister of State, Minister of Foreign Affairs, Senegal Cherif Mohamed Aly Aidara - Shi'i religious leader, NGO founder, and international development leader Cheikh Hamidou Kane Mathiara - former Minister of the Armed Forces, Senegal Daouda Sow (politician)- Politician and legislator, former Minister and former president of the National Assembly, Senegal Doudou Ka - Former Minister of Economy, Planning and Cooperation, Senegal. Doudou Thiam - First Foreign Minister, Senegal. Djibo Leyti Kâ – Held multiple ministerial positions Including Foreign Affairs, National Education, Interior, Communication etc. in Senegal Fatoumata Ka - first female mayor in Senegal, mayor of the commune of Diourbel.
Sources: en.wikipedia.org
=== Buffalo population and role in economy === As per the Food and Agriculture Organization of the United Nations (FAO), report, the global buffalo population was 148 million in 1992. Asia has 98% of the global buffalo population of nearly 194 million. In 2003, India had 98 million water buffalo (57% of world's buffalo population), followed by 23 million (12% of world's buffalo population) in China, and 3.2 million (1.6% of world's buffalo population) swamp-type carabao in the Philippines. Buffalo play an important part in India's national and rural economy.
=== Phototherapy === Phototherapy is considered a second-line treatment for vitiligo. Due to the higher risks of skin cancer with ultraviolet A (UVA) light, the United Kingdom's National Health Service suggests that it be used only if primary treatments are ineffective. The risk of skin cancer with UVB is unclear and commercially available lamps are not regulated, but 311 nm is considered the most effective wavelength, with the combined intake of antioxidant supplements believed to suppress oxidative stress. UVA treatments are normally carried out in a hospital clinic. Psoralen and ultraviolet A light (PUVA) treatment involves taking a drug that increases the skin's sensitivity to ultraviolet light and then exposing the skin to high doses of UVA light. Treatment is required twice a week for 6–12 months or longer. Due to the high doses of UVA and psoralen, PUVA may cause side effects such as sunburn-type reactions or skin freckling. Broadband ultraviolet B therapy is given three times a week. Narrowband ultraviolet B (NBUVB) phototherapy lacks the side effects caused by psoralens and is as effective as PUVA. Treatment is carried out 2–3 times weekly in a clinic. Longer treatment is often recommended over at least 6 months. The most effective responses are on the face and neck. Topical calcineurin inhibitors plus phototherapy produces better results than phototherapy alone, hydrocortisone plus laser light is better than laser light alone, ginkgo biloba is better than placebo, and oral mini-pulse of prednisolone (OMP) plus NB-UVB is better than OMP alone.
=== Primary source === Cyclooxygenase-1 and cyclooxygenase-2 metabolize arachidonic acid to the 15-hydroperoxy, 20 carbon prostaglandin (PG) intermediate, PGG2, and then to the 15-hydroxy, 20 carbon intermediate, prostaglandin H2 (PGH2). Thromboxane synthase further metabolizes PGH2 to the 20 carbon product, thromboxane A2, the 17 carbon product, 12-HHT, and the 3 carbon product, malonyldialdehyde. Platelets express cyclooxygenase and thromboxane synthase enzymes, producing PGG2, PGH2, and TXA2 in response to platelet aggregating agents such as thrombin; these metabolites act as autocrines by feeding back to promote further aggregation of their cells of origin and as paracrines by recruiting nearby platelets into the response as well as exerting effects on other nearby tissues such as contracting blood vessels. These effects combine to trigger blood clotting and limiting blood loss. 12-HHT is a particularly abundant product of these pro-clotting responses, accounting for about one third of the total amount of arachidonic acid metabolites formed by physiologically stimulated human platelets. Its abundant production during blood clotting, the presence of cyclooxygenases and to a lesser extent thromboxane synthase in a wide range of cell types and tissue, and its production by other pathways imply that 12-HHT has one or more important bioactivities relevant to clotting and, perhaps, other responses.
The two substrates of this enzyme are D-glyceric acid and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are hydroxypyruvic acid, reduced NADH and a proton. The enzyme can alternatively use nicotinamide adenine dinucleotide phosphate as its cofactor. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is D-glycerate:NADP+ 2-oxidoreductase. Other names in common use include beta-hydroxypyruvate reductase, NADH:hydroxypyruvate reductase, and D-glycerate dehydrogenase. This enzyme participates in glycine, serine and threonine metabolism and glyoxylate and dicarboxylate metabolism.
During sample preparation, the sample buffer, and thus SDS, is added in excess to the proteins, and the sample is then heated to 95 °C for five minutes, or alternatively 70 °C for ten minutes. Heating disrupts the secondary and tertiary structures of the protein by disrupting hydrogen bonds and stretching the molecules. Optionally, disulfide bridges can be cleaved by reduction. For this purpose, reducing thiols such as β-mercaptoethanol (β-ME, 5% by volume), dithiothreitol (DTT, 10–100 millimolar), dithioerythritol (DTE, 10 millimolar), tris(2-carboxyethyl)phosphine or tributylphosphine are added to the sample buffer. After cooling to room temperature, each sample is pipetted into its own well in the gel, which was previously immersed in electrophoresis buffer in the electrophoresis apparatus. In addition to the samples, a molecular-weight size marker is usually loaded onto the gel. This consists of proteins of known sizes and thereby allows the estimation (with an error of ± 10%) of the sizes of the proteins in the actual samples, which migrate in parallel in different tracks of the gel. The size marker is often pipetted into the first or last pocket of a gel.
Sources: en.wikipedia.org
=== Books === Chromatographic Determination of Molecular Interactions (1994) ISBN 9780849344374 Physicochemical and Biomimetic Properties in Drug Discovery: Chromatographic Techniques for Lead Optimization (2014) ISBN 9781118152126 Separation Methods in Drug Synthesis and Purification (2020) ISBN 9780444640703
International law experts argued that the operation may have violated international law. On 3 January 2026, United Nations Spokesperson Stéphane Dujarric issued a statement that said the UN Secretary-General António Guterres was "deeply alarmed by the recent escalation in Venezuela" and that United States' military action "has potential worrying implications for the region". Lawyer Geoffrey Robertson stated that the strike on Venezuela was contrary to Article 2(4) of the UN Charter and qualifies as a crime of aggression under international law. Elvira Domínguez-Redondo, professor of international law at Kingston University, also stated the strike was an act of aggression and that it could only have been lawful if it had authorization by a United Nations Security Council resolution, or was justified as "self-defense", but she added that there was "no evidence whatsoever" to support either condition. Ben Saul, a UN special rapporteur and professor of international law, condemned "the US's illegal aggression against Venezuela and the illegal abduction of its leader and his wife" and called on Trump to be investigated and impeached. Professor of international law Michael N. Schmitt, law professor Ryan Goodman and Tess Bridgeman concluded that the operation against Venezuela "amounts to a severe breach of foundational principles of international law". Professor of law Ziyad Motala described the "intervention in Venezuela to abduct President Nicolás Maduro" as "international vandalism, plain and unadorned".
== History == Scientists in Japan began to collaborate as early as 1939 on the development of an electron microscope. Kenji Kazato and Kazuo Ito met while working at the Naval Central Institute in Tokyo during World War II. After the war, Kazato attracted Ito and a group of others to Mobara, Chiba Prefecture, Japan. This initial group developed a prototype magnetic field–type electron microscope called the DA-1, which was sold to Mitsubishi in 1947. Because of differences over the direction of this early company, Kazato and Ito chose to found a new organization. The Japan Electron Optics Laboratory Company, Limited (Nihon Denshi Kogaku Kenkyujo) was founded in 1949 by Kenji Kazato and Kazuo Ito in Mitaka, Tokyo. It produced its first commercial model transmission electron microscope, the JEM-1, a year later. Overseas sales began in 1956 with the sale of a system to France. The company's strengths were the customization of orders to fit customer requests, and the provision of strong customer support. In 1961, the company was renamed JEOL, Limited. Its first overseas subsidiary, JEOL Company (USA) Inc., was established in 1962 and headquartered in Peabody, MA. JEOL was listed on the Second Section of the Tokyo Stock Exchange by 1962, and on the First Section of the Tokyo Stock Exchange by 1966. The company expanded from electron microscopy to nuclear magnetic resonance (NMR), releasing the first NMR system in Japan, the JNM-1, in 1956. They produced their first mass spectrometer in 1963, and their first scanning electron microscope in 1966.
== Medical uses == Oveporexton is indicated for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in adults. Narcolepsy type 1 is a rare, lifelong neuropsychiatric sleep disorder. It is caused by the loss of brain cells that produce orexin, a chemical messenger that regulates wakefulness, sleep, and muscle tone. Without orexin, the brain struggles to maintain alertness or to control the boundary between sleep and waking. The result is a cluster of disabling symptoms, including excessive daytime sleepiness, cataplexy (sudden muscle weakness triggered by strong emotions such as laughter), sleep paralysis, hallucinations at the edge of sleep or waking, and disrupted nighttime sleep. The effectiveness and safety of oveporexton were evaluated in two randomized, double-blind, placebo-controlled 12-week studies enrolling 273 adults with narcolepsy type 1. Across both studies, participants taking oveporexton 2 mg showed improvements in their ability to stay awake during the day compared with those receiving placebo. Participants also reported substantially less daytime sleepiness, a significant reduction in cataplexy episodes, and meaningful improvement across the full spectrum of narcolepsy symptoms, including sleep paralysis, hallucinations, and disrupted nighttime sleep.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.